Featured Research

from universities, journals, and other organizations

New Forecasting Tool Could Reduce Drug Development Costs

Date:
February 12, 2007
Source:
Children's Hospital Boston
Summary:
It now costs more than $800 million to develop a new drug. But what if pharmaceutical companies could predict which experimental drugs will ultimately get FDA approval, and which will ultimately fail? Researchers present a forecasting model that could potentially save hundreds of millions of dollars per new drug. They also urge more data sharing by the drug industry to improve the accuracy of forecasting, allowing more medical discoveries to be brought to the bedside.

It now costs more than $800 million to develop a new drug. But what if pharmaceutical companies had a way to predict which experimental drugs will ultimately get FDA approval, giving them the confidence to invest money in them, and which drugs will ultimately fail, allowing them to cut their losses early?

In the February issue of Nature Reviews Drug Discovery, researchers from the Children's Hospital Boston Informatics Program (CHIP) present a forecasting model that may increase the efficiency of drug R&D and save hundreds of millions of dollars per new drug. They also argue that more data sharing by the drug industry -- particularly of "negative" data -- would greatly improve the accuracy of forecasting and benefit industry and patients alike, allowing more medical discoveries to be brought to the bedside.

Asher Schachter, MD, MMSc, MS, and Marco Ramoni, PhD, both of CHIP, constructed a Bayesian network model to calculate the probability that a given new drug would pass successfully through Phase III trials and receive New Drug Application (NDA) approval. Their approach differs from convention in modeling populations of drugs rather than populations of patients. They used publicly available safety and efficacy data for about 500 successful and failed new drugs, broken down by therapeutic category, then confirmed the validity of their model by testing it with a group of cancer drugs whose fates are already known.

To gauge the model's potential economic impact, Schachter and Ramoni then performed a pharmaco-economic analysis in collaboration with Stan Finkelstein, MD, Senior Research Scientist at the MIT Sloan School of Management. This analysis, using summary data on industry-reported expenditures and revenues, indicated that application of the model would reduce mean capitalized expenditures by an average of $283 million per successful new drug (from $727 to $444), and increase revenues by an average of $160 million per Phase III trial (from $347 to $507 million) during the drug's first seven years on the market.

Schachter, also a pediatric nephrologist at Children's Hospital Boston, believes that more data sharing by the pharmaceutical industry would enable the industry to learn more from its own failures. "There's a tendency in the industry to bury data on failed drugs and forget about them," Schachter says. "We hope our model will add fuel to efforts to show that data-sharing could be beneficial to everybody."

Such efforts include legislation introduced in the Senate last year (S3807) that would establish a clinical trial registry database that would report the results of later-stage clinical trials, both good and bad.

In their report in Nature Reviews Drug Discovery, Schachter and Ramoni also argue that more accurate clinical forecasting would eliminate unsafe investigational new drugs; avoid subjecting patients to unnecessary drug trials; reduce the cost of prescription drugs for consumers; and empower the industry to take risks on truly innovative new drugs, so that more get to market.

The need for pharmaceutical industry involvement in early trials is especially acute for pediatric drugs, Schachter adds. Companies are reluctant to conduct clinical trials in children, fearing a negative impact on marketability. Instead, doctors often resort to giving adult drugs to children off-label, outside the context of a controlled, safety-monitored study.

For more information on the model and related issues, visit: http://phorecaster.com.


Story Source:

The above story is based on materials provided by Children's Hospital Boston. Note: Materials may be edited for content and length.


Cite This Page:

Children's Hospital Boston. "New Forecasting Tool Could Reduce Drug Development Costs." ScienceDaily. ScienceDaily, 12 February 2007. <www.sciencedaily.com/releases/2007/02/070201093600.htm>.
Children's Hospital Boston. (2007, February 12). New Forecasting Tool Could Reduce Drug Development Costs. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2007/02/070201093600.htm
Children's Hospital Boston. "New Forecasting Tool Could Reduce Drug Development Costs." ScienceDaily. www.sciencedaily.com/releases/2007/02/070201093600.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins